Coya Therapeutics, Inc. (COYA) 10-Year Financial Performance & Capital Metrics

COYA • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutCoya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.Show more

Revenue $4M -40.8%
EBITDA -$17M -118.7%
Net Income -$15M -86.3%
EPS (Diluted) -0.98 -24.1%
Gross Margin -233.86% -2903.6%
EBITDA Margin -484.58% -269.3%
Operating Margin -485.35% -268.6%
Net Margin -418.7% -214.6%
ROE -39.57% +32.5%
ROIC -609.36% +15.3%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Shares diluted 49.9% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-58.26%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-72.29%

EPS CAGR

10Y-

5Y-

3Y-

TTM-63.24%

ROCE

10Y Avg-83.33%

5Y Avg-83.33%

3Y Avg-107.53%

Latest-44.96%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	6M	3.55M
Revenue Growth %	-	-	-	-	-0.41%
Cost of Goods Sold+	0	0	4.41M	5.5M	11.87M
COGS % of Revenue	-	-	-	0.92%	3.34%
Gross Profit+	0	0	-4.41M	500.68K	-8.31M
Gross Margin %	-	-	-	0.08%	-2.34%
Gross Profit Growth %	-	-	-	1.11%	-17.6%
Operating Expenses+	1.04M	4.87M	5.4M	8.4M	8.94M
OpEx % of Revenue	-	-	-	1.4%	2.51%
Selling, General & Admin	668.7K	2.31M	4.85M	7.83M	8.89M
SG&A % of Revenue	-	-	-	1.31%	2.5%
Research & Development	373.45K	2.54M	4.94M	6.04M	11.89M
R&D % of Revenue	-	-	-	1.01%	3.35%
Other Operating Expenses	0	16.13K	-4.39M	-5.47M	-11.84M
Operating Income+	-1.04M	-4.87M	-9.81M	-7.9M	-17.25M
Operating Margin %	-	-	-	-1.32%	-4.85%
Operating Income Growth %	-	-3.67%	-1.01%	0.19%	-1.18%
EBITDA+	-337.5K	-4.85M	-9.78M	-7.88M	-17.22M
EBITDA Margin %	-	-	-	-1.31%	-4.85%
EBITDA Growth %	-	-13.38%	-1.02%	0.2%	-1.19%
D&A (Non-Cash Add-back)	704.65K	16.13K	27.36K	27.36K	27.36K
EBIT	-704.65K	-4.87M	-9.29M	-7.36M	-17.22M
Net Interest Income+	-38.98K	0	0	0	0
Interest Income	0	0	0	0	0
Interest Expense	38.98K	0	0	0	0
Other Income/Expense	-57.64K	-21.48K	-2.43M	639.37K	1.65M
Pretax Income+	-1.1M	-4.89M	-12.24M	-7.26M	-15.6M
Pretax Margin %	-	-	-	-1.21%	-4.39%
Income Tax+	0	0	0	723.85K	-720.29K
Effective Tax Rate %	1%	1%	1%	1.1%	0.95%
Net Income+	-1.1M	-4.89M	-12.24M	-7.99M	-14.88M
Net Margin %	-	-	-	-1.33%	-4.19%
Net Income Growth %	-	-3.45%	-1.5%	0.35%	-0.86%
Net Income (Continuing)	-1.1M	-4.89M	-12.24M	-7.99M	-14.88M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.42	-0.74	-1.23	-0.79	-0.98
EPS Growth %	-	-0.76%	-0.66%	0.36%	-0.24%
EPS (Basic)	-0.42	-0.74	-1.23	-0.79	-0.98
Diluted Shares Outstanding	2.59M	6.6M	9.95M	10.16M	15.24M
Basic Shares Outstanding	2.59M	6.6M	9.95M	10.16M	15.24M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	8.75M	4.58M	7.18M	41.2M	44.31M
Cash & Short-Term Investments	8.72M	4.34M	5.93M	32.63M	38.34M
Cash Only	8.72M	4.34M	5.93M	32.63M	38.34M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	1K	0	0	7.5M	730.58K
Days Sales Outstanding	-	-	-	456.08	75.03
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	0	0	0	0
Total Non-Current Assets+	0	207.85K	1.21M	65.95K	38.59K
Property, Plant & Equipment	0	120.67K	93.31K	65.95K	38.59K
Fixed Asset Turnover	-	-	-	91.01x	92.10x
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	0	87.18K	1.12M	0	0
Total Assets+	8.75M	4.79M	8.4M	41.26M	44.35M
Asset Turnover	-	-	-	0.15x	0.08x
Asset Growth %	-	-0.45%	0.75%	3.91%	0.07%
Total Current Liabilities+	447.12K	1.15M	3.82M	5.05M	3.82M
Accounts Payable	447.12K	857.57K	1.82M	1.16M	1.59M
Days Payables Outstanding	-	-	150.16	76.67	48.85
Short-Term Debt	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	923.11K	848.29K
Other Current Liabilities	0	0	0	0	0
Current Ratio	19.57x	3.99x	1.88x	8.15x	11.59x
Quick Ratio	19.57x	3.99x	1.88x	8.15x	11.59x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	0	0	12.97M	574.68K	945.45K
Long-Term Debt	0	0	12.97M	0	0
Capital Lease Obligations	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0
Total Liabilities	447.12K	1.15M	16.79M	5.63M	4.77M
Total Debt+	0	0	12.97M	0	0
Net Debt	-8.72M	-4.34M	7.03M	-32.63M	-38.34M
Debt / Equity	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-26.74x	-	-	-	-
Total Equity+	8.3M	3.64M	-8.39M	35.64M	39.58M
Equity Growth %	-	-0.56%	-3.3%	5.25%	0.11%
Book Value per Share	3.21	0.55	-0.84	3.51	2.60
Total Shareholders' Equity	8.3M	3.64M	-8.39M	35.64M	39.58M
Common Stock	259	259	259	1.44K	1.67K
Retained Earnings	-731.98K	-5.62M	-17.87M	-25.86M	-40.74M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	0	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-391.27K	-3.9M	-7.24M	-11.19M	-10.29M
Operating CF Margin %	-	-	-	-1.86%	-2.89%
Operating CF Growth %	-	-8.98%	-0.85%	-0.55%	0.08%
Net Income	-733K	-4.89M	-12.24M	-7.99M	-14.88M
Depreciation & Amortization	0	16.13K	27.36K	27.36K	27.36K
Stock-Based Compensation	0	233.22K	207.35K	872.25K	2.66M
Deferred Taxes	0	399.68K	0	0	0
Other Non-Cash Items	263.78K	-399.68K	4.02M	543.19K	25K
Working Capital Changes	77.95K	739.17K	751.84K	-4.64M	1.88M
Change in Receivables	0	0	0	-7.5M	7.5M
Change in Inventory	0	0	0	0	0
Change in Payables	105.22K	665.17K	845.28K	298.82K	477.45K
Cash from Investing+	0	-136.8K	-525K	-543.19K	-25K
Capital Expenditures	0	-136.8K	0	0	0
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	-525K	-543.19K	-25K
Cash from Financing+	9.11M	-340.58K	9.36M	38.43M	16.03M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	400	-341.9K	-1.11M	89.95K	2.02M
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-391.27K	-4.04M	-7.24M	-11.19M	-10.29M
FCF Margin %	-	-	-	-1.86%	-2.89%
FCF Growth %	-	-9.33%	-0.79%	-0.55%	0.08%
FCF per Share	-0.15	-0.61	-0.73	-1.10	-0.68
FCF Conversion (FCF/Net Income)	0.36x	0.80x	0.59x	1.40x	0.69x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-13.25%	-81.9%	-	-58.64%	-39.57%
Return on Invested Capital (ROIC)	-	-	-	-719.76%	-609.36%
Gross Margin	-	-	-	8.34%	-233.86%
Net Margin	-	-	-	-133.08%	-418.7%
Interest Coverage	-26.74x	-	-	-	-
FCF Conversion	0.36x	0.80x	0.59x	1.40x	0.69x
Revenue Growth	-	-	-	-	-40.79%

Frequently Asked Questions

Growth & Financials

Coya Therapeutics, Inc. (COYA) reported $4.0M in revenue for fiscal year 2024.

Coya Therapeutics, Inc. (COYA) saw revenue decline by 40.8% over the past year.

Coya Therapeutics, Inc. (COYA) reported a net loss of $18.4M for fiscal year 2024.

Dividend & Returns

Coya Therapeutics, Inc. (COYA) has a return on equity (ROE) of -39.6%. Negative ROE indicates the company is unprofitable.

Coya Therapeutics, Inc. (COYA) had negative free cash flow of $2.84B in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener